INDV Stock Overview
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£7.37 |
| 52 Week High | UK£17.51 |
| 52 Week Low | UK£5.55 |
| Beta | 0.26 |
| 1 Month Change | -3.73% |
| 3 Month Change | -18.89% |
| 1 Year Change | -54.84% |
| 3 Year Change | -47.28% |
| 5 Year Change | 268.25% |
| Change since IPO | -1.80% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Indivior PLC's (LON:INDV) Revenues Yet As Shares Tumble 26%
Feb 21
A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb
Nov 15Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump
Sep 24Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story
Aug 09Indivior PLC's (LON:INDV) Shares Not Telling The Full Story
May 29Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why
May 03We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Apr 10The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More
Feb 28Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?
Dec 11We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Oct 15We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Jun 27Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet
Mar 29Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly
Nov 24Shareholder Returns
| INDV | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -3.3% | -2.6% | -2.2% |
| 1Y | -54.8% | 5.8% | 6.8% |
Return vs Industry: INDV underperformed the UK Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: INDV underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| INDV volatility | |
|---|---|
| INDV Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 8.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: INDV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: INDV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,041 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
Indivior PLC Fundamentals Summary
| INDV fundamental statistics | |
|---|---|
| Market cap | UK£934.30m |
| Earnings (TTM) | UK£1.55m |
| Revenue (TTM) | UK£917.86m |
594.1x
P/E Ratio1.0x
P/S RatioIs INDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDV income statement (TTM) | |
|---|---|
| Revenue | US$1.19b |
| Cost of Revenue | US$190.00m |
| Gross Profit | US$998.00m |
| Other Expenses | US$996.00m |
| Earnings | US$2.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.016 |
| Gross Margin | 84.01% |
| Net Profit Margin | 0.17% |
| Debt/Equity Ratio | -95.7% |
How did INDV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 19:21 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior PLC is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Brian White | Cantor Fitzgerald Europe |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |